Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 4/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440138 | 0.90 | CHRM1 (0.44) | CHRM1PDE2APDE11AENPP3ENPP1 | |
| SCHEMBL17443020 | 0.87 | TP53 (0.44) | CHRM1PARP1ENPP3ENPP1GRM2 | |
| SCHEMBL17443026 | 0.80 | LTA4H (0.46) | CHRM1PDE2APDE11APOLBMAPT | |
| SCHEMBL17450434 | 0.79 | MAPK14 (0.39) | CHRM1PDE2APDE11AGRM2 | |
| SCHEMBL17439990 | 0.78 | CHRM1 (0.62) | CHRM1PDE2APDE11A | |
| SCHEMBL17440139 | 0.78 | TP53 (0.45) | CHRM1ENPP3ENPP1TP53POLB | |
| SCHEMBL17443029 | 0.77 | PARP1 (0.43) | CHRM1PARP1ENPP3ENPP1TP53 | |
| SCHEMBL17443022 | 0.76 | PARP1 (0.45) | CHRM1PARP1ENPP3ENPP1TP53 | |
| SCHEMBL17440006 | 0.76 | CHRM1 (0.78) | CHRM1PDE2APDE11A | |
| SCHEMBL17440066 | 0.75 | TP53 (0.47) | ENPP3ENPP1TP53POLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | PFIZER INC. (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016907-A1 | PYRIDINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885PARP1 2844/4885PDE2A 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.